KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaborative Agreement Revenue BreakdownCollaborative Agreement Revenue Breakdown AnnualCommercial Revenue By CategoryCommercial Revenue By Category AnnualContractual Obligations AnnualContractual Obligations TotalCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Income TaxNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant And Equipment, Net BreakdownRaw Materials By SegmentR&D Revenue By CategoryR&D Revenue By Category AnnualR&D Revenue By Category (Deprecated)Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ionis Pharmaceuticals (IONS) Gross Profit (2021 - 2025)

Ionis Pharmaceuticals (IONS) has disclosed Gross Profit for 9 consecutive years, with $243.1 million as the latest value for Q1 2026.

  • For Q1 2026, Gross Profit rose 86.79% year-over-year to $243.1 million; the TTM value through Mar 2026 reached $866.7 million, up 22.64%, while the annual FY2025 figure was $927.8 million, 33.7% up from the prior year.
  • Gross Profit hit $243.1 million in Q1 2026 for Ionis Pharmaceuticals, up from $195.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $321.4 million in Q4 2023 and bottomed at $117.3 million in Q1 2024.
  • Average Gross Profit over 5 years is $179.0 million, with a median of $154.4 million recorded in 2025.
  • Year-over-year, Gross Profit surged 156.52% in 2022 and then plummeted 30.7% in 2024.
  • Ionis Pharmaceuticals' Gross Profit stood at $148.2 million in 2022, then skyrocketed by 116.89% to $321.4 million in 2023, then crashed by 30.7% to $222.7 million in 2024, then fell by 12.29% to $195.4 million in 2025, then rose by 24.43% to $243.1 million in 2026.
  • According to Business Quant data, Gross Profit over the past three periods came in at $243.1 million, $195.4 million, and $154.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.